Choose HA†
Prescribing Information   |  OAKneePainRelief.com
Durolane_header_large_3800x1715-VA-final

Choose the Power of 1 for Your Military Patients Living with Knee OA*

  • Can relieve OA knee pain for 6 months24
  • Total joint residence time of approximately 150 days, based on a half-life of 30 days.†48,35
  • Highest reported molecular weight of any HA indicated for the treatment of knee OA43,46

US veterans and active-duty military deserve the best medical treatments available. DUROLANE for knee OA pain can be part of that solution.

Get in touch with a Rep

A single-injection hyaluronic acid (HA) therapy for knee osteoarthritis, DUROLANE offers important benefits for treatment of knee OA pain.

Durolane_middlesection_2880x1400-VA-final

Longer-Lasting Knee Pain Relief vs. Steroid11
In a Level 1 study, DUROLANE was proven to be noninferior to steroid at 6 weeks.11

Questions? Contact Us

How can we help you and your patients?

To learn more about DUROLANE, contact a rep by emailing BioventusIS@Bioventus.com or send your questions to us in the form below.

    I am a:












    Disclaimer: Bioventus will never make your email address available to third parties, except to distribute requested materials. Any complaints or adverse reaction messages may be sent to Complaints@Bioventus.com.

    †Preclinical residence time has not been correlated with the duration of clinical effect.

     

    DUROLANE, GELSYN-3 and SUPARTZ FX are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g., acetaminophen. Risks include general knee pain and pain at the injection site.

    View Use and Important Safety Information at: DUROLANE.com, GELSYN3.com, and SUPARTZFX.COM

    Summary of Indications for Use:
    DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

    Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

    DUROLANE has not been tested in pregnant or lactating women, or children.

    Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

    Summary of Indications for Use:
    GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

    GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

    Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

    Summary of Indications for Use:
    SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

    Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.